Recombinant DNA Technology Innovation and Growth in Healthcare

Recombinant DNA Technology Innovation and Growth in Healthcare

What is Recombinant DNA and its uses in Healthcare?

Recombinant DNA technology is a technique of manipulating and isolating DNA segments of interest using enzymes and various laboratory procedures. This approach is useful for combining (or splicing) DNA from various species or for creating genes with new functions. The resultant copies are known as recombinant DNA. The recombinant DNA is normally been  propagate in a bacterial or yeast cell, whose biological machinery copies the modified DNA alongside its own.

The recombinant DNA technology market was worth $707.20 billion in 2021 and will reach $1378.76 billion by 2030, at a CAGR of 7.7% during 2021-2030.

 

Recombinant DNA Market: Drivers and Restraints

The increasing burden of chronic diseases, the commercial success of biopharmaceuticals, genetically modified crops, bio insecticides, and other reasons. The expansion of the recombinant DNA market despite the presence of a solid biopharmaceutical pipeline, there is a growing need to boost recombinant protein production capacity by many orders of magnitude, owing to an increase in demand for effective therapies for disease treatment.

Genetically modified organisms are increasingly being in use in agriculture; more than half of the U.S. soybean crop consists entirely of a genetically modified strain; recombinant DNA is one of the most rapidly and widely accepted agricultural breakthroughs in recent years. As a result, the utilization of rDNA technology for non-traditional applications is expecting to increase.

The high complexity and large investment required to create a manufacturing facility for recombinant DNA synthesis and the low adoption of genetically modified crops are impeding the growth of the recombinant DNA market.

 

Key Opportunity

CRISPR, or clustered regularly interspaced short palindromic repeats, is a way by which prokaryotes fight themselves against viruses. In 2015, Science Magazine named the CRISPR genome editing tool the “Breakthrough of the Year.” The FDA in the United States approved a clinical trial in 2018 to use the CRISPR/Cas mechanism of gene editing as a therapeutic for persons with a gene mutation that causes blindness at birth. The vast and unknown application of this technology represents a huge opportunity for recombinant DNA technology.

 

Segmentation analysis

  • On the basis of product, the recombinant DNA technology market is been break down into specialty chemicals, vaccines, therapeutic agents, and genetically modified crops. In 2020, the therapeutic agent ruled the overall recombinant DNA technology market. The FDA has approved various therapeutic agents used for various conditions and diseases.

 

  • In terms of components, the industry is been break down into cloning vectors and expression systems. The market share of expression systems is expecting to grow.

 

  • On the basis of application, the recombinant DNA technology market is segmented into the environment, health and disease, and food & agriculture. Throughout the period, the health and diseases segment is expecting to hold a commanding position. There is also a growing demand for this technology in treating animals. As there is a growing demand for various drugs and vaccines that help in the improvement of the health of consumers, the market is expected to grow in the coming years.

 

Regional Analysis

North America held a significant position in the overall market, with a market share of more than 51% in 2021. Because many of the leading market players are in the United States, this region is expecting to be advantageous for the expansion of this technology. In the United States, regulatory bodies or the power for the approval of various items that use technology are also present. This technology is in use in the development of genetically engineered crops.

The European region is likewise expecting to perform well in the next years. The ability of better infrastructure for R&D operations in the North American and European regions will be the fastest growing market in the coming years. The quality of various healthcare facilities is expecting to improve during the projection period. Due to an increase in investments made by governments of various nations across the North American and European regions.

Increased collaboration and penetration in developing countries are projected to create stronger prospects for growth in the coming years.

Key players

  • BASF
  • Monsanto
  • Biogen
  • Novo Nordisk
  • DuPont Pioneer
  • Thermo Fisher Scientific Inc.
  • Other Players
contributor

Related Articles

Leave a Reply

Your email address will not be published.